These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37740667)

  • 21. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.
    Maneeton N; Maneeton B; Woottiluk P; Likhitsathian S; Suttajit S; Boonyanaruthee V; Srisurapanont M
    Drug Des Devel Ther; 2016; 10():259-76. PubMed ID: 26834458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
    Saha KB; Bo L; Zhao S; Xia J; Sampson S; Zaman RU
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010631. PubMed ID: 27045703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials.
    Schneider-Thoma J; Kapfhammer A; Wang D; Bighelli I; Siafis S; Wu H; Hansen WP; Davis JM; Salanti G; Leucht S
    Syst Rev; 2021 Aug; 10(1):214. PubMed ID: 34340713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.
    Findling RL; Pathak S; Earley WR; Liu S; DelBello MP
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):325-35. PubMed ID: 24956042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Hsu TW; Liang CS
    BMJ Ment Health; 2023 Feb; 26(1):. PubMed ID: 36789916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
    Bartkó G
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
    Iketani R; Kawasaki Y; Yamada H
    Biol Pharm Bull; 2017; 40(11):1976-1982. PubMed ID: 29093347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.
    Pan PY; Lee MS; Yeh CB
    BMC Psychiatry; 2015 Jan; 15():1. PubMed ID: 25609320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia.
    Akhlaq M; Maryam F; Elaissari A; Ullah H; Adeel M; Hussain A; Ramzan M; Ullah O; Zeeshan Danish M; Iftikhar S; Aziz N
    Drug Deliv; 2018 Nov; 25(1):916-927. PubMed ID: 29649903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels.
    Mauri MC; Volonteri LS; Fiorentini A; Pirola R; Bareggi SR
    Expert Opin Pharmacother; 2007 Oct; 8(14):2207-13. PubMed ID: 17927477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quetiapine: dose-response relationship in schizophrenia.
    Sparshatt A; Jones S; Taylor D
    CNS Drugs; 2008; 22(1):49-68; discussion 69-72. PubMed ID: 18072814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME).
    Karamustafalıoğlu O; Reif A; Atmaca M; Gonzalez D; Moreno-Manzanaro M; Gonzalez MA; Medina E; Bellomo A
    BMC Psychiatry; 2014 Aug; 14():246. PubMed ID: 25174996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
    Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
    Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.